Stock Details
ALPMF is Astellas Pharma Inc.'s stock. Stock exchange Other OTC (Currency USD). Average price in 50 days is 15.40$. Average daily volumn in 3 months 1.61k. Market cap 30.53B



Stock symbol : ALPMF. Exchange : Other OTC. Currency : USD
Lastest price : 16.71$. Total volume : 500.00. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Astellas Pharma Inc. (ALPMF)
Last Price
16.71$
Change
0.00
Volume
500.00

Previous Close16.71
Open16.71
Day Range16.71-16.71
Bid0.00 x N/A
Ask0.00 x N/A
Volume500
Average Volume1.61k
Market Cap30.53B
Beta0.64
52 Week Range14.56-17.95
Trailing P/E34.10
Foward P/EN/A
Dividend (Yield %)2.82%
Ex-Dividend Date2022-09-29



Financial Details


According to Astellas Pharma Inc.'s financial reports the company's revenue in 2022 were 1.3T an increase(0%) over the years 2021 revenue that were of 1.25T. In 2022 the company's total earnings were 124.09B while total earnings in 2021 were 120.59B( +3.33%).


Loading ...



Organization

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatme... nt of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Market Cap:
30.53B
Revenue:
1.3T
Total Assets:
2.33T
Total Cash:
315.99B



News about "Astellas Pharma Inc."

astellas-sutro-collaborate-to-advance-novel-immunostimulatory-antibody-drug-conjugates-image

Astellas, Sutro Collaborate To Advance Novel Immunostimulatory Antibody-Drug Conjugates

Source from : Nasdaq - 4 days ago

Sutro Biopharma Inc. (STRO) announced a worldwide, strategic collaboration and licensing agreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates or iADCs ...See details»


Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Grows By 1,087.9%

Source from : ETF Daily News - 3 days ago

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Rating Shares of Astellas Pharma stock opened at $16.14 on Wednesday. The company has a market cap of $29.63 billion, a PE ratio of 26.90, a price-to ...See details»


astellass-pompe-disease-gene-therapy-trial-put-on-fda-clinical-hold-image

Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold

Source from : YAHOO!Finance - 5 days ago

FORTIS Phase 1/2 trial following a serious adverse event (SAE) of peripheral sensory neuropathy in one of the trial participants. FORTIS trial is evaluating AT845, an investigational adeno-associated ...See details»


Generian and Astellas Enter into Collaboration and Exclusive License Agreement to Discover and Develop Novel Small Molecules For Undruggable Targets

Source from : Business Insider - 3 days ago

June 29, 2022 /PRNewswire/ -- Generian Pharmaceuticals, Inc. ("Generian") and Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma Inc.) announced today that they have entered into a ...See details»


astellas-pharma-submits-fezolinetant-nda-to-fda-image

Astellas Pharma Submits Fezolinetant NDA To FDA

Source from : Nasdaq - 8 days ago

Astellas Pharma Inc. said that it has submitted new drug application for fezolinetant to the U.S. Food and Drug Administration. Fezolinetant is an investigational oral, nonhormonal compound seeking ...See details»


astellas-announces-fda-update-on-the-fortis-clinical-trial-of-at845-in-adults-with-late-onset-pompe-disease-image

Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease

Source from : WFMZ-TV - 5 days ago

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that the US Food and Drug Administration (FDA) has placed a ...See details»


Astellas Submits Fezolinetant New Drug Application to U.S. FDA

Source from : Associated Press - 8 days ago

Application targets treatment of moderate to severe vasomotor symptoms associated (VMS) with menopause. TOKYO, June 23, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, Presi ...See details»


Sutro Biopharma Shares Rise 24% After Collaboration With Astellas Pharma

Source from : MarketWatch - 4 days ago

Sutro Biopharma Inc. shares rose 24% to $5.36 after the company said it entered into a worldwide strategic collaboration and licensing agreement with Astellas Pharma Inc. The company said the ...See details»


Pittsburgh biotech company Generian lands partnership with pharmaceutical company

Source from : The Business Journals - 2 days ago

Generian announced an exclusive license agreement with Mitobridge Inc., a division of Astellas Pharma Inc., on the discovery and development of small molecules that would treat rare diseases that ...See details»


Sutro Biopharma Shares Soar 67% on Cancer Treatment Collaboration with Astellas

Source from : MarketWatch - 4 days ago

By Patrick Chu Sutro Biopharma Inc. shares leaped 67% to $7.24 a share in U.S. after-hours trading after the South San Francisco biotech company said it ...See details»


Astellas, Sutro Biopharma ink collaboration to advance novel immunostimulatory antibody-drug conjugates

Source from : Pharmabiz - 3 days ago

Astellas, Sutro Biopharma ink collaboration to advance novel immunostimulatory antibody-drug conjugates: Tokyo Wednesday, June 29, 2022, 12:00 Hrs [IST] Astellas Pharma Inc. and S ...See details»


generian-and-astellas-enter-into-collaboration-and-exclusive-license-agreement-to-discover-and-develop-novel-small-molecules-for-undruggable-targets-image

Generian and Astellas Enter into Collaboration and Exclusive License Agreement to Discover and Develop Novel Small Molecules For Undruggable Targets

Source from : WFMZ-TV - 3 days ago

PITTSBURGH and CAMBRIDGE, Mass. , June 29, 2022 /PRNewswire/ -- Inc. ("Generian") and Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma Inc.) announced today that they have ...See details»


Astellas Pharma Submits Fezolinetant NDA To FDA

Source from : Business Insider - 5 days ago

(RTTNews) - Astellas Pharma Inc. said that it has submitted new drug application for fezolinetant to the U.S. Food and Drug Administration. Fezolinetant is an investigational oral, nonhormonal ...See details»


Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

Source from : YAHOO!Finance - 4 days ago

Astellas Pharma Inc. (TSE: 4503), (President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Sutro Biopharma, Inc. (NASDAQ: STRO), (CEO: William J. Newell, JD, "Sutro") today announced a worldwide, ...See details»